Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

With the successful launch of Novartis’ Pluvicto and Lutathera, more firms are developing radioligands in the hopes of mitigating side effects and addressing unmet needs in cancer. 

Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.